These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 15750457

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA.
    Vaccine; 2007 Jan 22; 25(6):1121-5. PubMed ID: 17045366
    [Abstract] [Full Text] [Related]

  • 5. Absence of a significant interaction between a Haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine.
    Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Vidor E, Liu X.
    Pediatr Infect Dis J; 2000 Aug 22; 19(8):710-7. PubMed ID: 10959738
    [Abstract] [Full Text] [Related]

  • 6. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL.
    Drugs; 2012 Sep 10; 72(13):1765-91. PubMed ID: 22931522
    [Abstract] [Full Text] [Related]

  • 7. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM.
    Pediatr Infect Dis J; 1998 Apr 10; 17(4):294-304. PubMed ID: 9576383
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children.
    Collins CL, Salt P, McCarthy N, Chantler T, Lane L, Hemme F, Diggle L, Buttery J, Kitchin NR, Moxon ER, Pollard AJ.
    Vaccine; 2004 Oct 22; 22(31-32):4262-9. PubMed ID: 15474717
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH.
    Vaccine; 2011 Feb 11; 29(8):1551-7. PubMed ID: 21215828
    [Abstract] [Full Text] [Related]

  • 10. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
    Bégué PC, Grimprel EM, Giovannangeli MD, Abitbol VI.
    Pediatr Infect Dis J; 1998 Sep 11; 17(9):804-9. PubMed ID: 9779766
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.
    Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granström M, Blondeau C, Hoffenbach A.
    Pediatr Infect Dis J; 1998 Nov 11; 17(11):1026-33. PubMed ID: 9849987
    [Abstract] [Full Text] [Related]

  • 12. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.
    Sänger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, Schmitz-Hauss E, Wolter J, Hoet B.
    Eur J Pediatr; 2007 Dec 11; 166(12):1229-36. PubMed ID: 17235521
    [Abstract] [Full Text] [Related]

  • 13. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R, Kuriyakose S, Mesaros N, Han HH, Tomlinson R, Faust SN, Snape MD, Pollard AJ, Finn A.
    Vaccine; 2018 Apr 19; 36(17):2300-2306. PubMed ID: 29576304
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 19; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.
    Yeh SH, Ward JI, Partridge S, Marcy SM, Lee H, Jing J, Curry ES, Howe BJ.
    Pediatr Infect Dis J; 2001 Oct 19; 20(10):973-80. PubMed ID: 11642632
    [Abstract] [Full Text] [Related]

  • 16. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, Elrick DB, Jacquet JM.
    Vaccine; 2006 May 01; 24(18):4017-23. PubMed ID: 16516357
    [Abstract] [Full Text] [Related]

  • 17. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
    Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B, Pentavac study group.
    Vaccine; 2004 Mar 29; 22(11-12):1406-14. PubMed ID: 15063563
    [Abstract] [Full Text] [Related]

  • 18. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
    Halperin SA, Smith B, Russell M, Scheifele D, Mills E, Hasselback P, Pim C, Meekison W, Parker R, Lavigne P, Barreto L.
    Pediatr Infect Dis J; 2000 Apr 29; 19(4):276-83. PubMed ID: 10783014
    [Abstract] [Full Text] [Related]

  • 19. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, Meekison W, Eastwood BJ.
    Pediatr Infect Dis J; 1999 Sep 29; 18(9):772-9. PubMed ID: 10493336
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.